Whereas TP53 mutations had been determined to arise pretty frequently in ALL (16%) [22] and AML (12%) [23,24], the frequencies are decreased in CLL (7%) [7,25,26,27] and MDS (6%) [28,29,30]. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.